COVID-19 Prevention

AstraZeneca to Supply Canada with 100,000 Doses of Evusheld, a Long-Acting Antibody Combination for the Prevention of COVID-19

AstraZeneca Canada

Clinical Data

New Fasenra® Data from the Meltemi Extension Trial Confirm Long-term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years

AstraZeneca

Drug Approval

Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes

AstraZeneca

COVID-19 Vaccine

HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine

HALIX

COVID-19 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into Phase III Clinical Trials

AstraZeneca

Breakthrough Therapy

Farxiga Granted Breakthrough Therapy Designation in U.S. for Chronic Kidney Disease

AstraZeneca

AstraZeneca, Oxford SARS-CoV-2 Vaccine Trials Temporarily Paused

AstraZeneca

COVID-19 Vaccine

Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222

Catalent

Clinical Trials

AstraZeneca Initiates Phase I Clinical Trial Initiated for Monoclonal Antibody Combination for COVID-19

AstraZeneca

Flu Vaccine

AstraZeneca Ships FLUMIST QUADRIVALENT Vaccine in the U.S. for 2020-2021 Flu Season

AstraZeneca

COVID-19 Vaccine

AstraZeneca Signs COVID-19 Vaccine Deal with Chinese Company

AstraZeneca

Collaboration

AstraZeneca and Daiichi Sankyo Enter Collaboration to Develop and Commercialize New Antibody Drug Conjugate

AstraZeneca

Approval

AstraZeneca's Breztri Aerosphere Approved in the US for the Maintenance Treatment of COPD

AstraZeneca

COVID-19 Vaccine

SGS Signs Analytical Testing Agreement with AstraZeneca for COVID-19 Vaccine Candidate

SGS Life Science Services

Clinical Results

AstraZeneca's Drug Significantly Reduces the Rate of the Composite of Stroke and Death in Patients

AstraZeneca

Vaccine Manufacturing

Daiichi Sankyo Announces Start of Discussions with AstraZeneca Regarding Supply in Japan of Novel Coronavirus Vaccine

Daiichi-Sankyo

Oncology

Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukemia in Two Trials

AstraZeneca

Partnership

ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring Assays for Minimal Residual Disease

ArcherDX

Collaboration

AstraZeneca to Discover and Develop Novel Therapies Targeting RNA-Modifying Proteins in Oncology Collaboration with Accent Therapeutics

AstraZeneca

Oncology

AstraZeneca Collaborates with ArcherDX to Use Personalized Cancer Assays to Detect Minimal Residual Disease in Lung Cancer Trials

AstraZeneca